Biothera Inc.

3m Innovative Properties Company

Keith B Gorden

Nandita Bose

Xiaohong Qiu

Anissa S H Chan

Michael E Danielson

John P Vasilakos

Mary A Antonysamy

William J Grossman

Steven M Leonardo

Jeremy Graff

Richard M Walsh

Nadine Ottoson

Peter Maimonis

Takashi Kangas

Kathryn A Fraser

Adria Bykowski Jonas

Ross Fulton

Anissa Sh Chan

Jason R Fink

Kevin S Gorski

Shalley K Gupta

Steven Leonardo

The invention generally relates to soluble beta-glucan compositions and method of using such compositions. In one aspect, an adjuvant for a pharmaceutical composition is described which includes a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen. In another aspect, compositions that generally include an antigen component, a soluble beta-glucan component, and a TLR agonist component and a method that generally includes administering to a subject a composition that comprises a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen, are described.

Compositions including beta-glucans and method of use

This disclosure relates to the combination of soluble &#x3b2;-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble &#x3b2;-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

&#x3b2;-glucan methods and compositions that affect the tumor microenvironment

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to &#x3b2;-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-&#x3b2;-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-&#x3b2;-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-&#x3b2;-glucan antibody.

Beta-glucan assay methods

The present invention relates to the combination of soluble &#x3b2;-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble &#x3b2;-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.

Beta-glucan compounds, compositions, and methods

&#x3b2;-glucan assay methods

Compositions including &#x3b2;-glucans and methods of use

Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.

Selective modulation of TLR-mediated biological activity

Methods of eliciting a TLR8-mediated cellular response are disclosed. Such methods include administration of either a TLR8 agonist or a TLR8 antagonist to an IRM-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.

Methods and compositions related to IRM compounds and Toll-like receptor 8

Growing community of inventors

Woodbury, MN, United States of America

Keith B Gorden